HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression

“…Unlike breast cancer, where there are high rates of concordance between HER2 expression and amplification, there is less correlation in ovarian cancer, which may be due to a number of factors such as nonstandardized HER2 testing methods, disease subtypes, or tumoral heterogeneity. [11][12][13] Intriguingly, the retrospective analysis of the initial diagnostic specimen revealed strong HER2 IHC, suggesting an opportunity for earlier treatment with a HER2 ADC if HER2 testing had been performed.…”

The HER2-low revolution in gynecological oncology: could it be a realistic emerging challenge?

“…In this complex scenario, the paper of Michaela Kendall Bártů et al [ 9 ] represents a thorough analysis of HER2 status in a stringently classified large clinical cohort of OCCCs ( n = 118).…”